Mingchun Luan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mingchun Luan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Keli Ma
Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, 116044, China
4 shared publications - Xiaohua Huang
Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, 116044, China; Department of Clinical Biochemistry, College of Laboratory Medicine, Dalian Medical University, Dalian, China
4 shared publications - Congcong Wang
Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, 116044, China
3 shared publications - Xiaoguang Ma
Department of Respirotory and Clinical Medecine, First Affiliated Hospital of Dalian Medical University, Dalian, China
3 shared publications - Xin He
Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, 116044, China
3 shared publications - Ying Li
Second Affiliated Hospital of Dalian Medical University
3 shared publications
Latest Publications
- 2 April 2021
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 147 (7) , 1927-1934
The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo
Background Tetraspanin KAI1/CD82, a tumor metastasis suppressor, has emerged as a promising molecular target for the management of metastatic disease. However, the peptide mimicking small extracellular ring domain (EC1) of CD82 has not been fully investigated for the function of inhibiting cell migration in vitro and tumor metastasis in vivo. Methods Different cancer cells were treated with EC1 mimic peptide in order to detect migration and invasion by the healing assay and transwell. Cell aggregation and adhesion assays were used to investigate the function of homotypic cell–cell aggregation and adhesion to tissue culture plates. Then, we established syngeneic and xenograft animal models to assess the metastasis inhibitory effect of EC1 mimic peptide in vivo. Results In vitro studies, the EC1 mimic peptide had been showed to promote homotypic cell–cell aggregation, suppress cell migration, invasion and adherence in multiple tumor cell types. In vivo metastasis assays, the EC1 mimic peptide could strongly inhibit the pulmonary metastasis of LCC in syngeneic mice model and SW620 and H1299 in xenograft mice model. Conclusion This novel finding will improve our understanding of the mechanism by which CD82 inhibits metastasis, and suggests that EC1 mimic peptide may be a promising candidate for developing anti-metastasis drugs.
- 2 April 2021
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 147 (7) , 1927-1934
The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo
Background Tetraspanin KAI1/CD82, a tumor metastasis suppressor, has emerged as a promising molecular target for the management of metastatic disease. However, the peptide mimicking small extracellular ring domain (EC1) of CD82 has not been fully investigated for the function of inhibiting cell migration in vitro and tumor metastasis in vivo. Methods Different cancer cells were treated with EC1 mimic peptide in order to detect migration and invasion by the healing assay and transwell. Cell aggregation and adhesion assays were used to investigate the function of homotypic cell–cell aggregation and adhesion to tissue culture plates. Then, we established syngeneic and xenograft animal models to assess the metastasis inhibitory effect of EC1 mimic peptide in vivo. Results In vitro studies, the EC1 mimic peptide had been showed to promote homotypic cell–cell aggregation, suppress cell migration, invasion and adherence in multiple tumor cell types. In vivo metastasis assays, the EC1 mimic peptide could strongly inhibit the pulmonary metastasis of LCC in syngeneic mice model and SW620 and H1299 in xenograft mice model. Conclusion This novel finding will improve our understanding of the mechanism by which CD82 inhibits metastasis, and suggests that EC1 mimic peptide may be a promising candidate for developing anti-metastasis drugs.
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (4) , 2206-2211
The peptide mimicking small extracellular loop domain of CD82 inhibits tumor cell migration, adhesion and induces apoptosis by inhibiting integrin mediated signaling
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (4) , 2206-2211
The peptide mimicking small extracellular loop domain of CD82 inhibits tumor cell migration, adhesion and induces apoptosis by inhibiting integrin mediated signaling